Bulletin
Investor Alert

July 23, 2021, 10:05 a.m. EDT

Immunotherapy Drugs Market Size 2021 Explosive Factors of Revenue By Progression Status, Emerging Demands, Recent Trends, Business Opportunity, Share and Forecast To 2027

The Immunotherapy Drugs Market is expected to exceed more than US$ 289.52 Billion by 2024 at a CAGR of 13% in the given forecast period.

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

8 Immunotherapy Drugs Market, By Therapy Area

9 Immunotherapy Drugs Market, By End User

10 Immunotherapy Drugs Market, By Region

11 Competitive Landscape

12 Company Profiles

12.1 Introduction

12.2 F. Hoffmann-La Roche AG

12.3 Merck & Co., Inc.

12.4 Novartis International AG

12.5 Johnson & Johnson (A Parent Company of Janssen Biotech, Inc.)

12.6 Glaxosmithkline PLC

12.7 Amgen Inc.

12.8 Abbvie

12.9 Astrazeneca

12.10 Bristol-Myers Squibb

12.11 ELI Lilly and Company

Other Related Market News :

http://www.marketwatch.com/story/personal-lubricant-market-industry-analysis-and-detailed-profiles-of-top-industry-players-the-covid-19-2021-07-21

http://www.marketwatch.com/story/personalized-medicine-market-industry-analysis-and-detailed-profiles-of-top-industry-players-the-covid-19-2021-07-21

http://www.marketwatch.com/story/petrochemicals-market-global-industry-analysis-size-share-growth-trends-and-forecast-2020—2025-2021-07-21

Media Contact

Company Name: Market Research Engine

Contact Person: John Bay

Email: john@marketresearchengine.com

Phone: +1-855-984-1862

Country: United States

Website: https://www.marketresearchengine.com/

COMTEX_390296676/2582/2021-07-23T10:05:12

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.